Articles related to Rheumatology

Explore the intriguing connections between postural orthostatic tachycardia syndrome (POTS) and autoimmune disorders. This comprehensive review offers insights into diagnosis, potential autoimmune mechanisms, and future directions in the field, providing valuable information for practitioners dealing with this complex condition.

Despite striking parallels in symptomatology between POTS and autoimmune disorders, a deeper scrutiny reveals that this overlap may not be sufficient to definitively attribute an autoimmune cause to POTS; hence, indiscriminate application of immunosuppressive therapies should be re-evaluated.

Exploring the multidimensional nature of fatigue in inflammatory arthritis patients uncovers the urgent need for a tailored, comprehensive approach in its management. Discover how an understanding of the complex interplay between physical, emotional, cognitive, and lifestyle factors can inform more effective patient care.

With research hinting at potential links between vitamin B6 and various health benefits, it’s time for physicians to delve deeper into the role of this micronutrient in optimizing patient health.

FDA Cautions Against Hidden Drug Ingredients in Joint Pain Supplements In response to recent findings, the FDA warns of significant health risks associated with three specific dietary supplements marketed for joint pain and rheumatoid arthritis relief due to the discovery of unlisted active pharmaceutical ingredients.

Unveiling a new path in osteoarthritis pain management, the FDA’s Breakthrough Therapy designation for resiniferatoxin marks a promising development. The FDA has granted Breakthrough Therapy designation to resiniferatoxin for treating osteoarthritis knee pain. Extracted from a cactus-like plant, resiniferatoxin, a potent TRPV1 agonist, boasts similarities to capsaicin. Notably, its potency sets it apart. Resiniferatoxin is administered through intra-articular injection, promoting pain relief by temporarily disabling TRPV1-expressing nociceptors. This unique mechanism targets one of the most profound symptoms of osteoarthritis: pain. Its potential benefits are eagerly awaited by millions of patients struggling with this relentless disease. Stepping up to the challenge, Grünenthal, the company behind resiniferatoxin, is launching a global Phase 3 program. They aim to enroll more than 1,800 patients with knee osteoarthritis who haven’t found sufficient relief from existing non-surgical treatments. With a focus on improved pain and physical function scores according to the WOMAC osteoarthritis index, the program’s efficacy endpoints are set for up to 52 weeks. Turning the tide in osteoarthritis treatment, the Breakthrough Therapy Designation offers an expedited path for this non-opioid therapy option. As Grünenthal’s Chief Scientific Officer, Jan Adams, optimistically noted, it is hoped that this designation will speed up resiniferatoxin’s availability to patients.